Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

BACKGROUND: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. METHODS: This systematic review inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazieh, Abdul-Rahman, Al Sudairy, Reem, Abu-Shraie, Nada, Al Suwairi, Wafaa, Ferwana, Mazen, Murad, M. Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821279/
https://www.ncbi.nlm.nih.gov/pubmed/24250733
http://dx.doi.org/10.4103/1817-1737.118503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821279/
https://www.ncbi.nlm.nih.gov/pubmed/24250733
http://dx.doi.org/10.4103/1817-1737.118503

Ejemplares similares